Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
When they examined tumor samples of glioblastoma, the deadliest form of brain cancer, researchers in Canada discovered they contained deactivated forms of specialized immune cells that normally fight tumor-generating cells. When they tested a drug that reactivates these immune cells in diseased mice, the animals lived two to three times longer.
The researchers, from the University of Calgary's Hotchkiss Brain Institute (HBI) and Southern Alberta Cancer Research Institute, hope their discovery will lead to clinical trials and eventually to a new standard of care for brain tumor patients.
They write about their findings in a recent online issue of Nature Neuroscience.
Even though treatments already exist, the median survival for patients with glioblastoma is only 15 months - fewer than 1 in 20 survive more than 5 years.
Our brains have their own specialized immune cells called microglia that protect against injury and infection.
They are the brain's "dedicated immune system," explains senior author V. Wee Yong, a professor in Calgary's Departments of Oncology and Clinical Neurosciences.
BTICs grow and divide rapidly, eventually forming a mass, the tumor itself.
And, as with cancers in other parts of the body, immune cells - like microglia - detect these kinds of cells and try to eliminate them.
Prof. Yong, who also holds a Canada Research Chair in Neuroimmunology, says:
"We refer to this as the battle for the brain, in which early on in the disease, the microglia are trying to destroy the brain tumor initiating cells. But over the course of time, the tumor disables the microglia and we start to see more initiating cells and more rapid tumor growth."
He explains that what they sought to do in their study was find a way "to tip the battle in favor of the brain to suppress the tumor."
In the first part of the study, he and his colleagues took microglia from patients without gliomas and cultured them with BTICs from patients with gliomas. They found that the microglia were able to arrest the growth of BTICs by inducing the expression of some of their genes.
Then in a second part of the study, in mice with brain tumors caused by mouse and human-derived BTICs, they found that daily doses of the drug amphotericin B (AmpB) reactivated microglia and led to a significant reduction in tumor growth.
First author and research associate Dr. Susobhan Sarkar says:
"This drug was able to reactivate the disabled microglia, thus restoring the body's natural defense mechanisms and restricting the growth of brain tumor initiating cells."
AmpB is a powerful drug that is already used to treat severe fungal infections of the brain and spinal cord.
"It's a rather harsh medication," says Prof. Yong. "But we have demonstrated that this drug can be used in very small doses where it is not only well tolerated, but it is also effective in re-programming microglia."
The team's discovery is already drawing attention from researchers in other parts of Canada. One of these is the internationally renowned neurosurgeon and brain tumor expert James Rutka, professor and chair of the Department of Surgery at the University of Toronto, who comments:
"This research is highly significant as it implies that a commercially available drug, amphotericin B, which has never been used before for patients with gliomas, may be a novel treatment to consider in future trials of patients with this frequently lethal cancer."
Funding from the study came from Alberta Innovates - Health Solutions/Alberta Cancer Foundation.
Earlier this year, a team from Johns Hopkins University School of Medicine in the US reported how they found a patient's own fat may help fight glioblastoma. They discovered a form of stem cell, called mesenchymal stem cells (MSCs), can hunt down cancer cells and that these stem cells are present in patients' own fat.
Written by Catharine Paddock PhD
Copyright: Medical News Today
Not to be reproduced without the permission of Medical News Today.
Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells; Susobhan Sarkar, Axinia Döring, Franz J Zemp, Claudia Silva, Xueqing Lun, and others; Nature Neuroscience published online 8 December 2013; DOI: 10.1038/nn.3597; Abstract.
Additional source: University of Calgary news release via EurekAlert 8 December 2013.
Visit our Cancer / Oncology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Paddock, Catharine. "Brain cancer treatment may lie in reactivating immune cells." Medical News Today. MediLexicon, Intl., 9 Dec. 2013. Web.
19 Apr. 2014. <http://www.medicalnewstoday.com/articles/269897>
Paddock, C. (2013, December 9). "Brain cancer treatment may lie in reactivating immune cells." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/articles/269897.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.